PharmaTimes World News
The latest news from PharmaTimes World News.
Updated: 12 hours 49 min ago
Biogen files fampridine PR in Europe, teams up with Trillium
Biogen Idec is asking regulators in Europe to approve a prolonged-release version of fampridine to improve walking in multiple sclerosis patients. It also noted that Tysabri sales have topped the $1 billion mark
US govt study probes “extraordinary” Rx price rises
Limited competition and a lack of therapeutically-equivalent drugs may be contributing to “extraordinary price rises” for branded medicines, a US government report claimed yesterday.
Alcon shareholders file lawsuit to stop 'brazen' Novartis takeover
A class action lawsuit has been filed in the USA on behalf of minority shareholders in Alcon who are trying to throw a spanner in the works of Novartis’ $39.1 billion takeover of the eye care specialist
FDA panel rejects expansion of Forest drug
Advisors to the US Food and Drug Administration have unanimously rejected Forest Laboratories attempt to market its antihypertensive Bystolic for the treatment of chronic heart failure
New year, new inflammatory bowel disease candidate for GSK
UK drug giant GlaxoSmithKline has kicked off the New Year by signing up for development and commercialisation rights to US group ChemoCentryx’ inflammatory bowel disease candidate Traficet-EN.
Galapagos signs major COPD deal with Roche
Shares in Galapagos are on the rise after the Belgian company signed an agreement with Roche which could be worth as much as 400 million euros
USA needs more time to review MannKind’s inhaled insulin
After a week of breathless predictions from industry observers, MannKind Corp has revealed that a US regulatory review of its inhaled insulin therapy Afrezza is going to take a bit longer
Hong Kong urged to tighten drug safety controls
Hong Kong’s Legislative Council Panel on Health Services will today consider recommendations aimed at improving the safety of the drug supply, including the establishment of a dedicated Centre for Drug Safety.
UK joins rest of Europe in shifting surplus swine flu vaccines
The UK is the latest European country to cancel orders of H1N1 flu vaccines as demand falls
FDA approves Roche's Actemra for RA
Roche is celebrating the news that regulators in the USA have given the green light to its rheumatoid arthritis drug Actemra
Reata signs kidney drug deal with Kyowa Hakko Kirin
The USA’s Reata Pharmaceuticals has secured a major deal with Japan’s Kyowa Hakko Kirin to develop and market its promising chronic kidney disease drug bardoxolone
EU opens antitrust proceedings against Lundbeck
The European Commission announced yesterday that it has opened a formal antitrust investigation into Danish drugmaker H Lundbeck.
Teva says revenues will double by 2015
Teva Pharmaceutical Industries has been outlining its plans for future growth to investors in New York, saying it expects to double revenues by 2015 to $31 billion
Troubled Genzyme gets backing of major shareholder
Genzyme Corp has received the support of a major shareholder amid rumours that billionaire investor Carl Icahn may be looking to get a presence on the board
Debiopharm to take on development of Pfizer cancer drug
Pfizer has signed a deal which will see Debiopharm take on late-stage development of a melanoma drug, tremelimumab, that the New York-based giant halted almost two years ago
Novo Nordisk signs “unique” Swedish academic pact
Novo Nordisk has signed what it calls an innovative research collaboration with Swedish university consortium Combine in the field of autoimmune diseases
AstraZeneca settles with Teva over generic Nexium
AstraZeneca has again fended off the threat of an imminent copycat version of its heartburn blockbuster Nexium hitting the US market by settling a patent dispute with Teva Pharmaceutical Industries
Almirall, Forest celebrate promising COPD drug data
Almirall and partner Forest Laboratories have reported positive results from a late-stage study of their investigational chronic obstructive lung disease drug aclidinium bromide
FDA approved 26 drugs in 2009, claims analysis
Regulators in the USA gave the green light to 26 new drugs last year, one more than in 2008, though have come under fire for missing too many deadlines for other potential therapies
US seniors “struggling with multiple medications”
25% of US seniors now take between 10 and 19 different prescription medicines each day, while 51% are taking at least five drugs daily, according to a new national survey.
